A new model to predict remission status in AML patients based on day 14 bone marrow biopsy
- 1 July 2016
- journal article
- Published by Elsevier BV in Leukemia Research
- Vol. 46, 69-73
- https://doi.org/10.1016/j.leukres.2016.04.013
Abstract
No abstract availableKeywords
Funding Information
- Leukemia & Lymphoma Society (2400-13)
- Gatorade Trust
This publication has 8 references indexed in Scilit:
- New strategies for the evaluation of the nadir bone marrow following induction in acute myeloid leukemiaCurrent Opinion in Hematology, 2013
- Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemiaLeukemia Research, 2012
- Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosisCancer, 2010
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetBlood, 2010
- Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemiaHaematologica, 2008
- Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemiaAmerican Journal of Hematology, 2008
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 TrialBlood, 2003